Search Results
Aug 29, 2025, 12:00 ET Biohaven Ltd. (BHVN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to
More news about: Law Offices of Howard G. Smith
Aug 29, 2025, 10:30 ET Faruqi & Faruqi Reminds Biohaven Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 12, 2025 - BHVN
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to
More news about: Faruqi & Faruqi, LLP
Aug 27, 2025, 12:53 ET BHVN Deadline: BHVN Investors with Losses in Excess of $100K Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to
More news about: THE ROSEN LAW FIRM, P. A.
Aug 27, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers - BHVN
is developing, among other product candidates, troriluzole for the treatment of spinocerebellar ataxia ("SCA"), among other indications, as well as BHV-7000 for the treatment of bipolar disorder, among other indications. In May 2022, a Phase 3 trial evaluating troriluzole's
More news about: Pomerantz LLP
Aug 26, 2025, 08:46 ET Class Action Filed Against Biohaven Ltd. (BHVN) - September 12, 2025 Deadline to Join - Contact Levi & Korsinsky
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (ii) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely
More news about: Levi & Korsinsky, LLP
Aug 25, 2025, 12:00 ET Biohaven Ltd. (BHVN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to
More news about: The Law Offices of Frank R. Cruz, Los Angeles
Aug 25, 2025, 08:45 ET Lost Money on Biohaven Ltd.(BHVN)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (ii) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely
More news about: The Gross Law Firm
Aug 22, 2025, 14:53 ET BHVN Deadline: BHVN Investors with Losses in Excess of $100K Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to
More news about: THE ROSEN LAW FIRM, P. A.
Aug 22, 2025, 10:05 ET SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biohaven
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to
More news about: Faruqi & Faruqi, LLP
Aug 22, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers - BHVN
is developing, among other product candidates, troriluzole for the treatment of spinocerebellar ataxia ("SCA"), among other indications, as well as BHV-7000 for the treatment of bipolar disorder, among other indications. In May 2022, a Phase 3 trial evaluating troriluzole's
More news about: Pomerantz LLP
Aug 22, 2025, 08:45 ET Contact Levi & Korsinsky by September 12, 2025 Deadline to Join Class Action Against Biohaven Ltd.(BHVN)
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (ii) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely
More news about: Levi & Korsinsky, LLP
Aug 21, 2025, 08:45 ET The Gross Law Firm Notifies Shareholders of Biohaven Ltd. (BHVN) of a Class Action Lawsuit and an Upcoming Deadline
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (ii) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely
More news about: The Gross Law Firm
Aug 20, 2025, 17:38 ET Biohaven Ltd. Stockholders are Urged to Seek Representation to Lead the BHVN Class Action: Contact Robbins LLP for More Information
is developing, among other product candidates, troriluzole for the treatment of spinocerebellar ataxia ("SCA"), among other indications, as well as BHV-7000 for the treatment of bipolar disorder, among other indications.
More news about: Robbins LLP
Aug 19, 2025, 12:00 ET Biohaven Ltd. (BHVN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to
More news about: Glancy Prongay & Murray LLP
Aug 19, 2025, 08:45 ET Shareholders that lost money on Biohaven Ltd.(BHVN) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (ii) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely
More news about: Levi & Korsinsky, LLP
Aug 18, 2025, 08:45 ET Lost Money on Biohaven Ltd.(BHVN)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (ii) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely
More news about: The Gross Law Firm
Aug 16, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers - BHVN
is developing, among other product candidates, troriluzole for the treatment of spinocerebellar ataxia ("SCA"), among other indications, as well as BHV-7000 for the treatment of bipolar disorder, among other indications. In May 2022, a Phase 3 trial evaluating troriluzole's
More news about: Pomerantz LLP
Aug 15, 2025, 15:56 ET Biohaven Ltd. (BHVN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to
More news about: Law Offices of Howard G. Smith
Aug 15, 2025, 09:28 ET Faruqi & Faruqi Reminds Biohaven Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 12, 2025 - BHVN
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to
More news about: Faruqi & Faruqi, LLP
Aug 15, 2025, 09:15 ET Class Action Filed Against Biohaven Ltd. (BHVN) Seeking Recovery for Investors - Contact Levi & Korsinsky
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (ii) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely
More news about: Levi & Korsinsky, LLP
Aug 14, 2025, 16:13 ET BHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to
More news about: THE ROSEN LAW FIRM, P. A.
Aug 14, 2025, 08:45 ET Biohaven Ltd. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - BHVN
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (ii) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely
More news about: The Gross Law Firm
Aug 12, 2025, 09:00 ET Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 12, 2025 in Biohaven Ltd. Lawsuit - BHVN
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (ii) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely
More news about: Levi & Korsinsky, LLP
Aug 11, 2025, 12:00 ET Biohaven Ltd. (BHVN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to
More news about: The Law Offices of Frank R. Cruz, Los Angeles
Aug 11, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers - BHVN
is developing, among other product candidates, troriluzole for the treatment of spinocerebellar ataxia ("SCA"), among other indications, as well as BHV-7000 for the treatment of bipolar disorder, among other indications. In May 2022, a Phase 3 trial evaluating troriluzole's
More news about: Pomerantz LLP